Overview and Scope
PEGylated proteins are therapeutic proteins covalently attached to polyethylene glycol (PEG) to enhance their pharmacokinetic properties and reduce immunogenicity, thus improving therapeutic efficacy. They are utilized in various medical applications, including drug delivery, diagnostics, and targeted therapy, offering prolonged action and improved patient outcomes.
Sizing and Forecast
The PEGylated proteins market size has grown rapidly in recent years. It will grow from $1.29 billion in 2023 to $1.47 billion in 2024 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to improved therapeutic efficacy, a growing aging population, demand for long-acting formulations, enhanced drug safety profiles, and expanding applications including targeted drug delivery systems.
The PEGylated proteins market size is expected to see rapid growth in the next few years. It will grow to $2.47 billion in 2028 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to increasing investment in rare diseases, rapid growth of the biopharmaceutical industry, precision medicine tailoring, increasing competition from biosimilar versions of biologic drugs, and adoption of innovative market access strategies. Major trends in the forecast period include the integration of digital health technologies, next-generation pegylation technologies, customized formulations for precision medicine, a focus on combination therapies, and a shift towards patient-centric healthcare models.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/pegylated-proteins-global-market-report
Segmentation & Regional Insights
The PEGylated proteins market covered in this report is segmented –
1) By Product: Consumable And Services, PEGylation Kits And Reagents, Monofunctional Linear PEGs, Bifunctional PEGs, Services, Other Products
2) By Protein Type: Colony Stimulating Factors, Interferons, Erythropoietin, Recombinant Factor VII, Other Protein Types
3) By Application: Cancer Treatment, Hepatitis, Chronic Kidney Diseases, Hemophilia, Multiple Sclerosis, Gastrointestinal Disorders, Other Applications
4) By End User: Pharmaceuticals, Biotechnology Companies, Contract Research Organizations, Academic Research Institutes
North America was the largest region in the PEGylated Proteins market in 2023. The regions covered in the PEGylated proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16145&type=smp
Major Driver Impacting Market Growth
The increasing prevalence rate of lifestyle diseases is expected to propel the growth of the PEGylated proteins market going forward. Lifestyle diseases refer to health conditions primarily caused by unhealthy habits and lifestyle choices such as poor diet, lack of physical activity, and smoking. Lifestyle diseases are on the rise due to a combination of factors such as less physical activity, unhealthier diets high in processed foods, and increased stress. PEGylated proteins are utilized in treating lifestyle diseases by enhancing the efficacy, duration, and targeted delivery of therapeutic agents for conditions including cardiovascular diseases, diabetes, and certain cancers. For instance, in October 2022, according to the World Heart Federation (WHF), a Switzerland-based non-governmental organization, the number of cardiovascular disease deaths is projected to rise from an estimated 18.9 million in 2020 to over 22.2 million in 2030. Additionally, in December 2021, according to the IDF Diabetes Atlas 10th Edition report published by the International Diabetes Federation, a Belgium-based diabetes community, 537 million adults aged 20 to 79 years worldwide were currently diagnosed with diabetes, representing 1 in 10 individuals. Therefore, the increasing prevalence rate of lifestyle diseases is driving the growth of the PEGylated proteins market.
Key Industry Players
Major companies operating in the PEGylated proteins market are Merck & Co. Inc., Bayer AG, Bristol Myers Squibb Company, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc., Novo Nordisk A/S, Evonik Industries AG, Viatris Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Lonza Group Ltd., Jazz Pharmaceuticals plc, Ipsen Pharma, Kyowa Kirin Co. Ltd., WuXi Biologics, BioMarin Pharmaceutical Inc., Ligand Pharmaceuticals Incorporated, Zydus Cadila, Enzon Pharmaceuticals Inc.
The pegylated proteins market report table of contents includes:
1. Executive Summary
2. PEGylated Proteins Market Characteristics
3. PEGylated Proteins Market Trends And Strategies
4. PEGylated Proteins Market – Macro Economic Scenario
5. Global PEGylated Proteins Market Size and Growth
.
.
.
32. Global PEGylated Proteins Market Competitive Benchmarking
33. Global PEGylated Proteins Market Competitive Dashboard
34. Key Mergers And Acquisitions In The PEGylated Proteins Market
35. PEGylated Proteins Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
